Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis

Completed · Phase 1/Phase 2

Conditions studied: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive

In brief

The purpose of the study is 1) to study the safety and tolerability of escalating doses of myelin peptide reactive T cells in MS patients and 2) to study the clinical effectiveness of T Cell Vaccine ion the clinical course of MS.

Key facts

Study ID

NCT00587691

Run by

Opexa Therapeutics, Inc.

People needed

16

Starts

2002-07-01

Expected to finish

2008-12-01

Last updated by the study team

2017-01-11

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stable MS disease within 30 days prior to enrollment
• EDSS Score between 2 and 8 inclusively
• Failed to respond to or cannot tolerate at least 1 or more of the currently approved drugs for MS.

You may not qualify if…

• Women who are pregnant or breast-feeding or who plan to become pregnant during the study
• Has taken immunomodulating drugs within 60 days prior to screening
• HIV positive

Where it is running

• Bellaire Neurology — Bellaire, Texas, United States
• Baylor College of Medicine — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.